Immutep Partners with GW Cancer Center for Efti Trial
Immutep Limited (NASDAQ: IMMP), a pioneering company in immunotherapy development, has recently announced an exciting collaboration with the George Washington University Cancer Center. This partnership aims to explore the efficacy of Efti, a novel cancer treatment, in patients with early-stage HR+/HER2-negative breast cancer. The trial will set out to evaluate Efti both as a standalone therapy and in conjunction with chemotherapy prior to surgical interventions.
Overview of the Phase II Trial
The Phase II trial is designed to assess the potential of Efti as a neoadjuvant treatment, which means it will be administered before the primary treatment, in this case, surgery. This clinical study is particularly significant as it will involve up to 50 patients, who will receive Efti to see how it influences the pathological complete response, a key measure of treatment effectiveness.
Unique Approach of Efti
Efti represents a groundbreaking approach in cancer treatment by leveraging the immune system to combat malignancies. Specifically, it works by activating antigen-presenting cells, promoting a robust immune response that has shown promise in both metastatic settings and early-stage disease. This initiative reflects the growing importance of immunotherapy in the treatment landscape for breast cancer.
Investigator Involvement and Leadership
Leading this important trial is Dr. Pavani Chalasani, MD, MPH, who is the Division Director of Hematology and Medical Oncology at GW Cancer Center. Dr. Chalasani expressed her optimism regarding this trial, citing her previous experiences with Efti, particularly in earlier studies that have yielded promising results in treating metastatic breast cancer.
Dr. Chalasani's Insights
Dr. Chalasani emphasized the significance of evaluating Efti in early-stage cancer patients, noting that the immune systems of these individuals may respond more favorably to such treatments. The hope is that the combination of Efti and chemotherapy will enhance the chances of achieving a complete pathological response, ultimately improving overall patient outcomes.
Objective of the Study
The overarching goal of this multi-center study is to determine how effectively Efti combined with neoadjuvant chemotherapy can lead to pathological complete response rates in participants. This information is crucial, as it can guide future treatment protocols and potentially reshape therapeutic strategies for breast cancer.
About Efti
Efti (Eftilagimod alfa) is Immutep's proprietary soluble LAG-3 protein that has garnered attention for its ability to stimulate both innate and adaptive immunity. The drug precisely activates immune cells that play a vital role in responding to tumors. Its unique mechanism not only targets cancer cells but also enhances the overall immune response, making it a strong candidate for treating a variety of cancers.
Immutep's Commitment to Innovation
Immutep is dedicated to advancing immunotherapy options for patients with unmet medical needs. With its strong focus on LAG-3, the company seeks to develop therapies that could significantly benefit patients battling cancer and autoimmune diseases. This trial with GW Cancer Center is a strategic step that aligns with its mission to deliver impactful treatment solutions.
Contacting Immutep
For inquiries or further information regarding this trial, stakeholders can reach out to the respective media contacts for Australian and U.S. investors. Eleanor Pearson and Chris Basta are available for questions regarding this innovative endeavor.
Frequently Asked Questions
What is the purpose of the trial involving Efti?
The trial aims to evaluate the effectiveness of Efti as a neoadjuvant treatment for patients with early-stage HR+/HER2-negative breast cancer, assessing its potential to improve patient outcomes when combined with chemotherapy.
Who is leading the trial at GW Cancer Center?
Dr. Pavani Chalasani, a clinical expert in hematology and oncology, is the principal investigator leading the trial.
How many patients will participate in the trial?
Up to 50 evaluable patients will be treated as part of the study.
What does Efti target in the immune system?
Efti works by activating antigen-presenting cells, which in turn stimulate a broad anti-cancer immune response, enhancing the body's ability to fight tumors.
Where can I find more information about the study?
Additional details about the trial can be found by visiting clinicaltrials.gov and searching for NCT07102940.
